2006
DOI: 10.1038/sj.bjc.6603391
|View full text |Cite
|
Sign up to set email alerts
|

Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial

Abstract: We conducted a non-randomised controlled phase II trial to investigate the role of preoperative administration of interleukin-2 (IL-2) in patients with renal cell carcinoma undergoing tumour nephrectomy. A total of 120 consecutive patients were allocated alternately to the two study groups: perioperative immunomodulation with IL-2 (IL-2 group; n ¼ 60) and perioperative immunomonitoring without immunomodulation (control group; n ¼ 60). Patients from the IL-2 group received four doses of 10 Â 10 6 IU m À2 twice … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
29
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(29 citation statements)
references
References 29 publications
0
29
0
Order By: Relevance
“…RCC is known as an immuno-sensitive tumour which is the basis of IL-2 and/or interferon (IFN)-based regimens for advanced RCC [15][16][17]. We showed in our earlier reports that perioperative immunodysfunction can be effectively modulated by treatment with IL-2 [18,19]. In addition, we reported evidence of a survival benefit for pre-treated patients [19].…”
Section: Introductionmentioning
confidence: 93%
“…RCC is known as an immuno-sensitive tumour which is the basis of IL-2 and/or interferon (IFN)-based regimens for advanced RCC [15][16][17]. We showed in our earlier reports that perioperative immunodysfunction can be effectively modulated by treatment with IL-2 [18,19]. In addition, we reported evidence of a survival benefit for pre-treated patients [19].…”
Section: Introductionmentioning
confidence: 93%
“…There is strong evidence in the animal setting that numerous agents that broadly stimulate the immune system are effective in significantly reducing the incidence of metastatic disease after surgery. Perioperative administration of recombinant IL-2 and IFN-a has been explored in early-phase clinical trials showing their potential to prevent postoperative NK cell suppression and enhance progression-free survival (23)(24)(25)(26)(43)(44)(45)(46)(47).…”
Section: Discussionmentioning
confidence: 99%
“…Alternatively, immune therapies are ideal candidates for perioperative administration. The perioperative administration of recombinant cytokines has been explored in early-phase clinical trials (23,24). These studies have shown that perioperative administration prevent the supression of NK cell activity that occurs following surgery (25,26).…”
Section: Introductionmentioning
confidence: 99%
“…The perioperative administration of cytokine therapy has been explored in early-phase clinical trials showing their potential to prevent postoperative NK cell suppression and enhance progression-free survival (17)(18)(19)(20)(21)(22)(24)(25)(26). However, further development has been limited due to dose-limiting toxicity (27)(28)(29).…”
Section: Introductionmentioning
confidence: 99%